Systemic Arterial and Venous Thrombotic Events Associated With Anti-Vascular Endothelial Growth Factor Injections: A Meta-Analysis

被引:2
作者
Jhaveri, Aaditeya [1 ]
Balas, Michael [1 ]
Khalid, Faran [2 ]
Mihalache, Andrew [1 ]
Popovic, Marko m. [3 ]
Kertes, Peter j. [3 ,4 ]
Muni, Rajeev h. [3 ,5 ,6 ]
机构
[1] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada
[2] McMaster Univ, Michael Groote Sch Med, Hamilton, ON, Canada
[3] Univ Toronto, Dept Ophthalmol & Vis Sci, , Toratario, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, Toronto, ON, Canada
[5] Dept Ophthalmol RHM, St Michaels Hospi tal Unity Hlth Toronto, Toronto, ON, Canada
[6] St Michaels Hosp Unity Hlth Toronto, Toronto, ON, Canada
关键词
INTRAVITREAL AFLIBERCEPT INJECTION; DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION; RANIBIZUMAB; DEGENERATION; SAFETY; BEVACIZUMAB; EFFICACY; OUTCOMES; THERAPY;
D O I
10.1016/j.ajo.2024.01.016
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To compare the risk of systemic arteriovenous thrombotic events between intravitreal antivascular endothelial growth factor (anti-VEGF) and sham injections. DESIGN: Random-effects meta-analysis. METHODS: A systematic search was performed on OVID MEDLINE, Embase, and Cochrane Library from January 2005 to August 2023. Our inclusion criteria were randomized controlled trials (RCTs) reporting on systemic arteriovenous events for standard dose intravitreal anti-VEGF agents for any indication. RESULTS: A total of 20 RCTs reporting on 12,833 eyes were included. There was no significant difference in the risk of any thrombotic event between bevacizumab 1.25 mg and ranibizumab 0.5 mg (Risk ratio (RR) = 0.96, 95% CI = 0.52-1.75, P = . 89). There was no significant difference between bevacizumab and ranibizumab when restricting to arterial thrombotic events (RR = 0.88, 95% CI = 0.60-1.30, P = . 53) or venous thrombotic events (RR = 1.99, 95% CI = 86 0.68-5.82], P = . 21). The risk of arterial thrombotic events was similar between aflibercept and bevacizumab (RR = 1.11, 95% CI = 0.60-2.07, P = . 74), between aflibercept and ranibizumab (RR = 0.77, 95% CI = 0.49-1.21, P = . 26), between brolucizumab and aflibercept (RR = 0.67, 95% CI = 0.321.38, P = . 27), and between aflibercept and faricimab (RR = 0.96, 95% CI = 0.43-2.17, P = .93). Compared to sham, neither dose of ranibizumab (0.5 mg or 0.3 mg) showed a higher risk of arterial thrombotic events. CONCLUSIONS: There was a similar risk of systemic arteriovenous thrombotic adverse events between anti VEGF agents and between ranibizumab and sham injections.
引用
收藏
页码:86 / 96
页数:11
相关论文
共 46 条
  • [1] Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema A Systematic Review and Meta-analysis
    Avery, Robert L.
    Gordon, Gabriel M.
    [J]. JAMA OPHTHALMOLOGY, 2016, 134 (01) : 21 - 29
  • [2] Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Two-Year Results
    Berg, Karina
    Hadzalic, Emina
    Gjertsen, Inger
    Forsaa, Vegard
    Berger, Lars Haakon
    Kinge, Bettina
    Henschien, Hans
    Fossen, Kristian
    Markovic, Slavica
    Pedersen, Terje R.
    Sandvik, Leiv
    Bragadottir, Ragnheiour
    [J]. OPHTHALMOLOGY, 2016, 123 (01) : 51 - 59
  • [3] Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE
    Brown, David M.
    Quan Dong Nguyen
    Marcus, Dennis M.
    Boyer, David S.
    Patel, Sunil
    Feiner, Leonard
    Schlottmann, Patricio G.
    Rundle, Amy Chen
    Zhang, Jiameng
    Rubio, Roman G.
    Adamis, Anthony P.
    Ehrlich, Jason S.
    Hopkins, J. Jill
    [J]. OPHTHALMOLOGY, 2013, 120 (10) : 2013 - 2022
  • [4] Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
    Campbell, Robert J.
    Gill, Sudeep S.
    Bronskill, Susan E.
    Paterson, J. Michael
    Whitehead, Marlo
    Bell, Chaim M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [5] Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study
    Campochiaro, Peter A.
    Brown, David M.
    Awh, Carl C.
    Lee, S. Young
    Gray, Sarah
    Saroj, Namrata
    Murahashi, Wendy Yee
    Rubio, Roman G.
    [J]. OPHTHALMOLOGY, 2011, 118 (10) : 2041 - 2049
  • [6] Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study
    Campochiaro, Peter A.
    Heier, Jeffrey S.
    Feiner, Leonard
    Gray, Sarah
    Saroj, Namrata
    Rundle, Amy Chen
    Murahashi, Wendy Yee
    Rubio, Roman G.
    [J]. OPHTHALMOLOGY, 2010, 117 (06) : 1102 - U111
  • [7] Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study
    Chakraborty, Debdulal
    Sengupta, Sabyasachi
    Mondal, Soumen
    Boral, Subhendu
    Das, Arnab
    Sinha, Tushar Kanti
    Bhattacharya, Ranabir
    Maitra, Ritobroto
    [J]. OPHTHALMOLOGY AND THERAPY, 2022, 11 (02) : 629 - 638
  • [8] Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
    Chakraborty, Debdulal
    Stewart, Michael W.
    Sheth, Jay U.
    Sinha, Tushar K.
    Boral, Subhendu
    Das, Arnab
    Mondal, Soumen
    Mukherjee, Angshuman
    [J]. OPHTHALMOLOGY AND THERAPY, 2021, 10 (02) : 337 - 348
  • [9] Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
    Chakravarthy, Usha
    Harding, Simon P.
    Rogers, Chris A.
    Downes, Susan M.
    Lotery, Andrew J.
    Culliford, Lucy A.
    Reeves, Barnaby C.
    [J]. LANCET, 2013, 382 (9900) : 1258 - 1267
  • [10] Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study
    Chang, Yin-Hsi
    Chien, Li-Nien
    Chen, Wan-Ting
    Lin, I-Chan
    [J]. PLOS ONE, 2022, 17 (04):